285 related articles for article (PubMed ID: 26954275)
1. Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.
Michel MC; Gravas S
Expert Opin Drug Saf; 2016 May; 15(5):647-57. PubMed ID: 26954275
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.
Rosa GM; Ferrero S; Nitti VW; Wagg A; Saleem T; Chapple CR
Eur Urol; 2016 Feb; 69(2):311-23. PubMed ID: 26422675
[TBL] [Abstract][Full Text] [Related]
3. A drug safety evaluation of mirabegron in the management of overactive bladder.
Robinson D; Thiagamoorthy G; Cardozo L
Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.
Ohlstein EH; von Keitz A; Michel MC
Eur Urol; 2012 Nov; 62(5):834-40. PubMed ID: 22695239
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
[TBL] [Abstract][Full Text] [Related]
6. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
[TBL] [Abstract][Full Text] [Related]
7. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
[TBL] [Abstract][Full Text] [Related]
10. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis.
Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY
World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972
[TBL] [Abstract][Full Text] [Related]
11. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
[TBL] [Abstract][Full Text] [Related]
12. Mirabegron (Myrbetriq) for overactive bladder.
Med Lett Drugs Ther; 2013 Feb; 55(1410):13-5. PubMed ID: 23459457
[No Abstract] [Full Text] [Related]
13. Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder.
Rosa GM; Baccino D; Valbusa A; Scala C; Barra F; Brunelli C; Ferrero S
Expert Opin Drug Saf; 2018 May; 17(5):487-497. PubMed ID: 29542337
[TBL] [Abstract][Full Text] [Related]
14. Selective β₃-adrenoceptor agonists for the treatment of overactive bladder.
Andersson KE; Martin N; Nitti V
J Urol; 2013 Oct; 190(4):1173-80. PubMed ID: 23458471
[TBL] [Abstract][Full Text] [Related]
15. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
Chapple CR; Kaplan SA; Mitcheson D; Blauwet MB; Huang M; Siddiqui E; Khullar V
Int J Urol; 2014 Oct; 21(10):960-7. PubMed ID: 25092441
[TBL] [Abstract][Full Text] [Related]
16. Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder.
Ellsworth P; Fantasia J
Expert Opin Investig Drugs; 2015 Mar; 24(3):413-9. PubMed ID: 25557359
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial.
Nitti VW; Chapple CR; Walters C; Blauwet MB; Herschorn S; Milsom I; Auerbach S; Radziszewski P
Int J Clin Pract; 2014 Aug; 68(8):972-85. PubMed ID: 24703195
[TBL] [Abstract][Full Text] [Related]
18. Mirabegron for the treatment of overactive bladder.
Gras J
Drugs Today (Barc); 2012 Jan; 48(1):25-32. PubMed ID: 22384458
[TBL] [Abstract][Full Text] [Related]
19. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.
Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N
Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283
[TBL] [Abstract][Full Text] [Related]
20. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence.
Sacco E; Bientinesi R; Tienforti D; Racioppi M; Gulino G; D'Agostino D; Vittori M; Bassi P
Expert Opin Drug Discov; 2014 Apr; 9(4):433-48. PubMed ID: 24559030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
